当前位置: X-MOL 学术J. Clinical Psychopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).
Journal of Clinical Psychopharmacology ( IF 2.9 ) Pub Date : 2019-11-7 , DOI: 10.1097/jcp.0000000000001129
Jurjen van der Schans 1 , Eelko Hak 1, 2 , Maarten Postma 1, 3, 4 , Laura Breuning 5 , Jacobus R B J Brouwers 1, 6 , Kaspar Ditters 7 , Paul A F Jansen 6 , Rob M Kok 8 , Jan G Maring 9 , Rob van Marum 10, 11 , Hans Mulder 12, 13 , Jaap Nanninga 7 , Richard C Oude Voshaar 14 , Arne J Risselada 12 , Liesbeth Vleugel 15 , Max Stek 15 , Ron H N van Schaik 16 , Elizabeth J J Berm 1 , Bob Wilffert 1, 17
Affiliation  

The duration of untreated depression is a predictor for poor future prognosis, making rapid dose finding essential. Genetic variation of the CYP2D6 isoenzyme can influence the optimal dosage needed for individual patients. The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine.

中文翻译:

CYP2D6 药物遗传学筛查在老年人开始使用去甲替林或文拉法辛治疗中的影响:实用随机对照试验(CYSCE 试验)。

未经治疗的抑郁症的持续时间是未来预后不良的预测因素,因此快速发现剂量至关重要。CYP2D6 同工酶的遗传变异会影响个体患者所需的最佳剂量。本研究的目的是确定 CYP2D6 药物遗传学筛查在加速使用去甲替林或文拉法辛的老年抑郁症患者的药物剂量方面的有效性。
更新日期:2020-12-17
down
wechat
bug